Turning Point Therapies, Lululemon, RH and others
Check out the companies making headlines before the bell: Turning Point Therapeutics (TPTX) — Shares of the biopharmaceutical company doubled in pre-market trading after approval of its acquisition by Bristol Myers Squibb (BMY) for $76 per share in cash, or $4.1 billion. Turning Point specializes in treating cancer. Lululemon (LULU) — Shares of Lululemon rose …
Turning Point Therapies, Lululemon, RH and others Read More »